This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts initiated coverage on several companies with positive ratings. Notably, Guggenheim initiated coverage on Six Flags Entertainment with a Buy rating and a $52 price target, while Jefferies rated RxSight as a Buy with a $72 target. Mizuho rated Evergy as Outperform with a $67 target, Barclays rated CRH as Overweight with a $110 target, and Rodman & Renshaw rated Quince Therapeutics as Buy with an $11 target.
October 29, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays initiated coverage on CRH with an Overweight rating and a $110 price target, indicating a positive outlook.
The Overweight rating and price target above the current price suggest a positive short-term impact on CRH's stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Mizuho initiated coverage on Evergy with an Outperform rating and a $67 price target, indicating a favorable outlook.
The Outperform rating and price target above the current price suggest a positive short-term impact on Evergy's stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Guggenheim initiated coverage on Six Flags Entertainment with a Buy rating and a $52 price target, suggesting potential upside.
The Buy rating and price target above the current price indicate a likely positive impact on Six Flags' stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Rodman & Renshaw initiated coverage on Quince Therapeutics with a Buy rating and an $11 price target, indicating a strong upside potential.
The Buy rating and price target significantly above the current price suggest a strong positive short-term impact on Quince Therapeutics' stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Jefferies initiated coverage on RxSight with a Buy rating and a $72 price target, indicating a positive outlook.
The initiation of coverage with a Buy rating and a price target significantly above the current price suggests a positive short-term impact on RxSight's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80